Hashimoto Thyroiditis vs Graves Disease: How to Tell Them Apart

Both Hashimoto thyroiditis and Graves disease are autoimmune disorders of the thyroid marked by circulating antibodies and, often, a goiter. The core axis that separates them is function and mechanism: Hashimoto is T-cell–mediated destruction leading ultimately to hypothyroidism, while Graves is antibody-mediated stimulation of the TSH receptor causing hyperthyroidism. Master the TSH/Free T4 pattern, the antibody profile, and the presence of ophthalmopathy and you can distinguish them reliably.

How to tell them apart

FeatureHashimoto thyroiditisGraves disease
Underlying mechanismAutoimmune T-cell–mediated destruction of thyroid follicular cells; anti-TPO and anti-thyroglobulin antibodies are markers, not the primary driverThyroid-stimulating immunoglobulins (TSI) bind and activate the TSH receptor, stimulating the gland unchecked by feedback
Net thyroid functionCauses primary hypothyroidism (most common cause in iodine-sufficient areas), progressing from subclinical to overtCauses primary hyperthyroidism (the most common cause)
TSH / Free T4 patternTSH elevated, Free T4 low (or normal in subclinical disease)TSH suppressed, Free T4 and Free T3 elevated
Antibody profileAnti-TPO antibodies positive in >90% of cases; anti-thyroglobulin antibodies may also be positiveTSI (thyroid-stimulating immunoglobulin) or TRAb (TSH receptor antibodies) positive
OphthalmopathyNo eye findingsOphthalmopathy — proptosis, lid retraction/lid lag, diplopia — is unique to Graves, driven by autoimmune inflammation of retroorbital tissues
DermopathyAbsentPretibial myxedema (dermopathy) may occur, though rare
Clinical symptomsLate disease produces hypothyroid featuresHyperthyroid features: heat intolerance, palpitations/tachycardia (may include atrial fibrillation), tremor, weight loss with increased appetite, anxiety, warm moist skin
Radioactive iodine uptake (RAIU)Not a gland overproducing hormone; the destructive process shows low uptakeDiffusely increased uptake across the gland, reflecting active overproduction (may not be needed if the clinical picture is classic)

The reasoning

Anchor first on the TSH/Free T4 pattern. TSH↑ with T4↓ signals primary hypothyroidism — check TPO antibodies, and their positivity clinches Hashimoto. TSH↓ with T4/T3↑ signals hyperthyroidism — then confirm the cause with RAIU or TSI/TRAb. In hyperthyroidism, diffusely increased RAIU plus positive TSI/TRAb establishes Graves. The single most decisive clinical arbiter is ophthalmopathy: prominent eyes with a hyperthyroid picture are specific to Graves. When the axis is unclear because Hashimoto is passing through an early hyperthyroid phase, use RAIU — a destructive process shows low uptake because it is not actively synthesizing hormone, unlike the high uptake of Graves.

Key tests

  • TSH with Free T4: Hashimoto shows elevated TSH with low Free T4; Graves shows suppressed TSH with elevated Free T4/T3.
  • Thyroid autoantibodies: anti-TPO (and often anti-thyroglobulin) positivity points to Hashimoto, while TSI/TRAb positivity confirms Graves.
  • Radioactive iodine uptake (RAIU): diffusely high uptake indicates overproduction as in Graves, whereas destructive/thyroiditis processes show low uptake because the gland is not synthetically active.

What they share

  • Both are autoimmune thyroid diseases with characteristic circulating antibodies as markers
  • Both can produce a goiter (Hashimoto may enlarge or, in the atrophic form, shrink; Graves classically gives a diffuse goiter)
  • Both can present with a hyperthyroid phase — Hashimoto transiently via 'hashitoxicosis' as stored hormone is released, and Graves as sustained hyperthyroidism
  • Both are most relevant thyroid autoimmune conditions in iodine-sufficient populations and are diagnosed starting with TSH

Pitfalls

  • Confusing early 'hashitoxicosis' with Graves: Hashimoto can cause transient hyperthyroidism from release of stored hormone before evolving to hypothyroidism — RAIU and antibody profile resolve the confusion.
  • Assuming a goiter distinguishes them — both can produce goiters, and Hashimoto may instead be atrophic without enlargement.
  • Forgetting that ophthalmopathy is specific to Graves and does not occur in Hashimoto (or in other causes of hyperthyroidism such as toxic nodules).
  • Treating a destructive/thyroiditis hyperthyroid phase with antithyroid drugs — they won't work when the gland is not overproducing hormone.
  • Over-relying on antibodies alone: anti-TPO can appear in autoimmune thyroid disease generally, so interpret antibodies alongside the TSH/T4 pattern and RAIU.

Practice this the way the exam tests it — on branching cases where your decisions shape the patient.